洛铂联合紫杉醇治疗晚期非小细胞肺癌的疗效与安全性研究

The study of the efficacy and safety of Lobaplatin plus Paclitaxel treating advanced non-small cell lung cancer

目的研究洛铂联合紫杉醇治疗晚期非小细胞肺癌的临床效果,探讨其临床适用性。方法 收集广东省中山市小榄镇2015年3月~2016年6月新发的40例晚期非小细胞肺癌患者作为研究对象,随机分为实验组和对照组,各20例。对照组患者给予紫杉醇联合卡铂治疗,实验组患者给予紫杉醇联合洛铂治疗,比较两组患者的临床疗效及不良反应发生情况。结果 对照组患者总有效率为70.00%,明显低于实验组的95.00%,差异有统计学意义（P〈0.05）。实验组的不良反应发生率均明显低于对照组,差异有统计学意义（P〈0.05）。结论 洛铂联合紫杉醇治疗晚期非小细胞肺癌的效果显著,不良反应发生率低,值得临床推广应用。

Objective To study the clinical efficacy of Lobaplatin plus Paclitaxel treating advanced non-small cell lung cancer,and to explore the clinical applicability.Methods From March 2015 to June 2016,40 cases of new advanced non-small cell lung cancer were collected as study object from Xiaolan Town in Zhongshan City of Guangdong Province and randomly divided into the control group and the observation group,each group had 20 cases.The control group was treated with Paclitaxel plus Carboplatin,the observation group was treated with Paclitaxel plus Lobaplatin.The clinical efficacy and the incidence of adverse reaction after treatment between two groups were compared.Results The total effective rate of the control group was 70.00% and it was obviously lower than that of the observation group（95.00%）,and the difference was statistically significant（P〈0.05）.The incidence of adverse reaction of the observation group was obviously lower than that of the control group,the difference was statistically significant（P〈0.05）.Conclusion The efficacy of Lobaplatin plus Paclitaxel treating advanced non-small cell pulmonary cancer is notable,the incidence of adverse reactions is lower, which is worthy of clinical promotion and application.